Microbiology & CCS

One antibiotic course, two delayed symptoms, how silent gut disruption connects acne and vaginal infections months later.

Hospitals aren't sterile, they're ecosystems. Microbial balance, not single pathogens, drives infection risk. See the 99% AMR-reduction trial data.

Mycoplasma is invisible to routine checks. Modern risk management combines prevention, rapid detection, and compliant response.

EU GMP Annex 1 made zero CFU the new Grade A standard. Here's how it's reshaping contamination control, EM programmes, and pharma microbiology.

How a compliant environmental monitoring programme became a blindfold, and what every sterile facility should ask before the next contamination event.

A 14-day sterility test can outlast a product's shelf life. Here's how RMMs cut detection time and stay FDA, EMA compliant.

Turbulence is the hidden contamination risk in sterile manufacturing, First Air, smoke studies, isolators and Annex 1 explained.

Biofilms resist antibiotics, evade immune defenses, and persist on medical devices. Here's why they remain one of pharma's toughest challenges.

ALCOA+ principles, common data integrity risks, OOS handling and audit trail best practices for pharma microbiology labs.

Could your gut bacteria decide if a drug works? Exploring how the microbiome shapes drug metabolism, immunotherapy response, and precision medicine.